POSITIVE DRUG LIST – NATURE OF THE PRICE REGULATION OF MEDICINAL PRODUCTS

dc.contributor.authorTankov, Vasil
dc.date.accessioned2025-07-01T20:34:14Z
dc.date.available2025-07-01T20:34:14Z
dc.date.issued2025
dc.description.abstractThe basis of drug pricing in our country is a specific legal-technical mechanism. This is the so-called Positive Drug List (PDL). Its legal framework is provided in the Law on Medicinal Products in Human Medicine (Art. 262 et seq.) and further developed in the Ordinance on the Conditions, Rules, and Procedures for Regulating and Registering of Prices for Medicinal Products. The purpose of this article is to provide a more detailed look at this specific subject matter, while offering the author's interpretation of the legal characteristics, structure, and functions of the PDL.
dc.identifier.issn2367-5314
dc.identifier.urihttps://doi.uni-plovdiv.bg/handle/store/645
dc.language.isoother
dc.publisherPlovdiv University Press
dc.relation.ispartofseries10.69085; si20251141
dc.subjectPositive Drug List
dc.subjectmedicinal products
dc.subjectpricing
dc.subjectreimbursement
dc.subjectAnatomical Therapeutic Chemical classification
dc.subjectATC code
dc.subjectInternational Non-proprietary Name
dc.subjectINN
dc.subjectreference pricing
dc.titlePOSITIVE DRUG LIST – NATURE OF THE PRICE REGULATION OF MEDICINAL PRODUCTS
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
si20251141.pdf
Size:
282.09 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
73 B
Format:
Item-specific license agreed to upon submission
Description:
Collections